News

19 09, 2023

BioProcess International – Cell & Gene Therapy Conference – 2023

2025-03-14T19:34:18+00:00

We are thrilled to announce that Avance Biosciences™ will be attending the highly anticipated Cell & Gene Therapy Manufacturing Conference, and we cordially invite you to join us! As a leader in advanced therapies, we understand the importance of staying at the forefront of cell and gene therapy innovation...

BioProcess International – Cell & Gene Therapy Conference – 20232025-03-14T19:34:18+00:00
12 09, 2023

FDA takes action on updated mRNA COVID-19 vaccines

2024-07-13T13:29:10+00:00

The mRNA COVID-19 vaccines approved and authorized today are supported by the FDA’s evaluation of manufacturing data to support the change to the 2023-2024 formula and non-clinical immune response data on the updated formulations including the XBB.1.5 component...

FDA takes action on updated mRNA COVID-19 vaccines2024-07-13T13:29:10+00:00
29 08, 2023

Gene Therapy Potency Assay Summit – 2023

2025-03-14T19:34:59+00:00

We are thrilled to announce that Avance Biosciences™ will be attending the highly anticipated Gene Therapy Potency Assay Summit, and we cordially invite you to join us! As a leader in advanced therapies, we understand the importance of staying at the forefront of gene therapy innovation...

Gene Therapy Potency Assay Summit – 20232025-03-14T19:34:59+00:00
29 08, 2023

FDA issues new draft guidelines on cell and gene therapy manufacturing changes

2024-07-10T19:48:28+00:00

Specifically, the guidance recommends conducting analytical comparability studies to provide scientific evidence of the impact that manufacturing changes may have on the safety, potency, and purity of human cellular and gene therapy products...

FDA issues new draft guidelines on cell and gene therapy manufacturing changes2024-07-10T19:48:28+00:00
23 08, 2023

First IND clearance for an allogeneic, off-the-shelf NK or CAR-T cell therapy candidate in autoimmune disease

2024-07-13T13:13:43+00:00

Artiva Biotherapeutics announced today that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application for AlloNK®, in combination with rituximab for treatment of systemic lupus erythematosus in patients with active lupus nephritis...

First IND clearance for an allogeneic, off-the-shelf NK or CAR-T cell therapy candidate in autoimmune disease2024-07-13T13:13:43+00:00
15 08, 2023

Study shows promise of gene therapy for alcohol use disorder

2024-07-10T19:47:42+00:00

A form of gene therapy currently used to treat Parkinson’s disease may dramatically reduce alcohol use among chronic heavy drinkers, researchers at Oregon Health & Science University and institutions across the country have found...

Study shows promise of gene therapy for alcohol use disorder2024-07-10T19:47:42+00:00
8 08, 2023

Study reveals new way to reduce friendly fire in cell therapy

2024-07-10T19:47:58+00:00

In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient’s T cells are engineered to better recognize and attack antigens on the surface of cancer cells. In treatments currently approved for use in battling lymphoma and leukemia...

Study reveals new way to reduce friendly fire in cell therapy2024-07-10T19:47:58+00:00
18 07, 2023

FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes

2023-07-18T13:27:31+00:00

The U.S. Food and Drug Administration approved Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of type 1 diabetes. Lantidra is approved for the treatment of adults with type 1 diabetes who are unable to approach target glycated hemoglobin (average blood glucose levels) because of current...

FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes2023-07-18T13:27:31+00:00
11 07, 2023

Enhancing Safety and Efficacy – Biodistribution Services for Advanced Cell and Gene Therapies

2023-07-11T18:18:43+00:00

As the field of advanced cell and gene therapies continues to grow exponentially, ensuring their safety and efficacy becomes paramount. Biodistribution studies, which evaluate the distribution of viral vectors and transgenes in the body, play a crucial role in pre-clinical pharmacokinetics and toxicity assessments...

Enhancing Safety and Efficacy – Biodistribution Services for Advanced Cell and Gene Therapies2023-07-11T18:18:43+00:00
27 06, 2023

A historic first for gene therapy

2023-06-27T12:46:28+00:00

Sarepta Therapeutics announces FDA approval of ELEVIDYS, the first gene therapy to treat Duchenne Muscular Dystrophy. ELEVIDYS addresses the root genetic cause of Duchenne – mutations in the dystrophin gene that result in the lack of dystrophin protein – by delivering a gene that codes for a shortened form of dystrophin to muscle cells known as ELEVIDYS micro-dystrophin...

A historic first for gene therapy2023-06-27T12:46:28+00:00
Go to Top